Australia Invests $1.9M in Groundbreaking Cancer Research Centre

Australia is set to advance its fight against cancer with the launch of a groundbreaking research centre dedicated to immunotherapy, a treatment that harnesses the body’s own immune system to target and destroy cancer cells. The Australian Cancer Research Foundation (ACRF) Centre for Dynamic Immuno-Oncology (CDIO), established in collaboration between Monash University and The Alfred hospital in Melbourne’s south-east, marks a significant investment in cancer research, with total funding exceeding AUD $1.9 million.

The CDIO, announced on 1 May 2026, will focus on real-time monitoring of a patient’s immune response to immunotherapy. By leveraging advanced imaging and cellular-level immunology tools, researchers aim to improve the detection of early anti-tumour effects and minimize side effects. The centre is headquartered at The Alfred’s Paula Fox Melanoma and Cancer Centre, with close ties to Monash University’s Alfred campus, creating a hub for integrated cancer research, diagnostics, and treatment.

Cutting-Edge Technology and Collaborative Research

The CDIO will utilize state-of-the-art technology, including the newly installed $24 million Quadra PET/CT scanner at The Alfred. This advanced scanner enables earlier detection of small cancers, faster and safer imaging, and real-time assessment of treatment progress. Such capabilities are expected to enhance both clinical trials and patient care, offering more personalized and effective cancer treatments.

Funding for the CDIO is provided by the Australian Cancer Research Foundation and the National Imaging Facility. The centre is part of Monash University’s new Department of Cancer Medicine, which aims to accelerate discoveries in cancer immunotherapy and improve outcomes for patients across Victoria and beyond.

Improving Immunotherapy Outcomes

Immunotherapy has revolutionized cancer treatment, offering new hope for patients with previously difficult-to-treat cancers. However, challenges remain in optimizing its effectiveness and minimizing adverse effects. The CDIO’s research will focus on understanding how a patient’s immune system responds to immunotherapy, enabling more precise and safer treatments.

Kerry Strydom, Chief Executive of the Australian Cancer Research Foundation, emphasized the importance of this research: Immunotherapy is one of the most significant innovations in cancer treatment—ever. Tapping into the power of advanced immune-monitoring technologies, the CDIO will track immune responses in patients, improving the safety and effectiveness of current and future immune-based cancer treatments.

Professor Mark Shackleton, Head of the new Monash Department of Cancer Medicine and Director of Oncology at The Alfred, highlighted the centre’s role in transforming cancer care: The clinicians and researchers here at The Alfred are generating information and evidence that will transform cancer care for patients, with universal benefit for years to come.

Broader Impact and Future Directions

The establishment of the CDIO is expected to position Victoria at the forefront of global immunology research. By integrating cutting-edge technology with clinical expertise, the centre aims to drive faster and more equitable improvements in cancer care, ultimately changing and saving lives.

Monash University’s Vice-Chancellor and President, Professor Sharon Pickering, underscored the collaborative effort behind the CDIO: The CDIO will bring together the most cutting-edge technology and the leading experts in cancer immunology to accelerate the discoveries we need to further the effectiveness of immunotherapies.

As research progresses, the CDIO is poised to contribute not only to local advancements but also to global efforts in cancer treatment, offering new insights and potential breakthroughs in the fight against cancer.